Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)
This grant supports the development of EU-based production of stable isotopes crucial for manufacturing radionuclides in novel nuclear medicine therapies. It aims to strengthen the security and resilience of the EU's medical radioisotope supply chain by securing access to source materials, reducing reliance on third countries, and enhancing industrial-scale production. The project leverages expertise among nuclear scientists, physicists, and engineers to develop and optimize EU-based isotope production, contributing to Europe’s Beating Cancer Plan and implementing the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA). The action prioritizes innovative, scalable, and cost-effective methods for producing stable isotopes (such as Yb-176), addresses dependency on Russian imports, and supports new opportunities and innovation in the EU nuclear medicine sector. Proposals should include close-to-market activities focused on technology readiness levels 5 to 7, with limited R&D.
| Agency | EURATOM (EU) |
|---|---|
| Region | EU |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Other |
| Start date | 24 Mar 2026 |
| End date | 15 Sep 2026 |
| Max funding | Innovation Actions: €2,000,000 and €3,000,000 per grant, Coordination and Support Actions: up to €7,000,000 per grant, Cofund Actions: up to €15,000,000 per grant |
| Budget | Innovation Actions (multiple topics): €10,000,000 across 2026–2027 Research and Innovation Actions: €15,000,000 across 2026–2027 Coordination and Support Actions: up to €7,500,000 across 2026–2027 Cofund Actions: €30,000,000 across 2026–2027 |
| Coverage | Funding is provided as lump sums according to Horizon Europe programme rules. |